Burlington, Ontario, & Dresden, Germany, September 05, 2023 – The Cultivated B (TCB) and denovoMATRIX have entered into a collaborative partnership to conduct a feasibility study with implications that enable the scalable, economically viable commercial production of cultivated meats. denovoMATRIX will contribute its microcarrier technology to test the proliferation of suspended cells in TCB’s bioreactors and cell mediums, and its coating technology for functionalizing scaffolding, which enables a structured final cultivated meat product. [Read more…]
Exo Biologic’s Phase 1/2 Trial is 1st MSC-derived Extracellular Vesicle Trial Approved by EMA
July 17, 2023, Liège, Belgium – EXO Biologics SA, a Belgian biotech company committed to developing biopharmaceuticals using Extracellular Vesicles (EVs) to treat rare diseases with high unmet medical needs, received approval from the European Medicines Agency (EMA) for the EVENEW study, enabling site activation in Europe. EVENEW is an adaptive, seamless Phase 1/2 trial assessing the safety and efficacy of intratracheal administration of EXOB-001 in preventing Bronchopulmonary Dysplasia (BPD) in preterm newborns. The EVENEW Study is the first mesenchymal stromal cell (MSC)-derived extracellular vesicles trial approved by the EMA. [Read more…]
Dr. A.J. Mellott, CEO and Co-Founder of Ronawk, Appointed as Director on the Board of the Biomedical Engineering Society (BMES)
Overland Park, KS – Ronawk, a trailblazing biotechnology company committed to advancing next-generation therapies through innovation powered by Roanwk’s Bio-Block™ platform, is delighted to announce that its CEO and Co-Founder, Dr.
A.J. Mellott, has been elected to serve as a Director on the esteemed Board of Directors of the Biomedical Engineering Society (BMES). [Read more…]
iPSirius Announces Clinical Trial Decisions and Secures New Patents in Japan and Israel
Paris, France – iPSirius today announced its decision to focus on advanced non-small cell lung cancer as the first indication for its comprehensive stem cell-based immunotherapy in the inaugural first-in-human clinical trial. Furthermore, the company declared its intention to apply for a clinical trial licence and undertake the clinical trial in the United Kingdom, to leverage the integrated clinical infrastructure, there, as well as take advantage of the country’s extensive biotech expertise and the UK government’s commitment to innovative healthcare solutions. [Read more…]
Celularity announces multi-year research collaboration services agreement with Regeneron
In major news that broke this morning, Celularity (CELU) has announced a partnership with Regeneron (REGN) to support the research, preclinical development, and manufacturing of allogeneic targeted cell therapy candidates targeting difficult-to-treat cancers.
The selection follows months of rigorous assessment and due diligence by Regeneron and showcases a high level of confidence and validation of Celularity’s core science, business model, and strategic vision. Celularity’s expertise in the off-the-shelf allogeneic cell therapy field is exceptional and includes the engineering and design of chimeric antigen receptors (CAR) for use with T and natural Killer (NK) cells. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 88
- Next Page »
